PRESS RELEASE

Woke Purchases Synthetic Psilocybin from Purisys for Formulation of Novel Dosage Forms

- Purchase of synthetic psilocybin to support formulation of novel dosage forms
- Monash MMIC has initiated formulation work with a surrogate molecule
- Purchase of API maintains planned trajectory of Phase IIb trials starting in 2022

15 November 2021 – **Woke Pharmaceuticals Pty Ltd** ('Woke' or 'the Company'), a Sydney NSW-based company focused on psychedelics for mental health, is pleased to announce that it has placed an initial purchase order of non-GMP (non-Good Manufacturing Process) synthetic psilocybin from Purisys LLC ('Purisys') for the formulation of novel dosage forms to treat depression.

Purisys is based in Athens, Georgia, specialising in the synthetic manufacture of Active Pharmaceutical Ingredients (APIs), including psychedelic drugs. The company has a United States Drug Enforcement Agency (DEA) licensed and FDA-inspected manufacturing facility with the required quality assurance and quality control to support Woke's supply chain needs.

Woke is developing two novel dosage forms of psilocybin for the treatment of depression. Both candidates are expected to commence Phase IIb trials in H2 CY2022. Woke has partnered with Monash University's Medicines Manufacturing Innovation Centre to formulate WP001, a novel low-dose (1mg – 5mg) rapid release capsule of psilocybin for the treatment of moderate depression. A second novel clinical candidate, WP002, is a higher dose (25mg) with concomitant psychotherapy, for treatment of major depressive disorder.

Mr Nick Woolf, CEO of Woke Pharmaceuticals, said: "Woke is focused on the development of synthetic psychedelics, both novel dosage forms of existing drugs such as psilocybin, but also novel analogues with enhanced properties. Our mission is to benefit patients suffering from mental health disorders with unmet medical needs. We are excited to have aligned with Purisys for API supply, thus ensuring our formulation work at Monash University remains on track. In Q1 CY2002, we anticipate a further order of GMP material for the manufacture of clinical material and commencing two seminal Phase IIb trials for depression later in the year."

Dr Joshua Hoerner, General Manager of Purisys, commented: "We have established synthetic technology and manufacturing expertise coupled with a strong track record of regulatory compliance to supply high quality psychedelic APIs. We look forward to expanding our relationship with Woke as they progress towards their planned clinical trials. There is significant interest from academics and pharmaceutical companies regarding psilocybin's potential as a treatment for depression and other mental health diseases, based on recent clinical data."

ENDS

This announcement was authorised for release by the Directors of Woke Pharmaceuticals.

For more information, please contact:

Mr Nick Woolf
CEO
info@wokeph.com
+61 417 986 005

PRESS RELEASE

Investor Relations: ir@havnlife.com 604 359 0060
Media: savi@emergence-creative.com 647 896 8078

ABOUT WOKE PHARMACEUTICALS

Woke Pharmaceuticals Pty Ltd is an Australian-based company focused on the development and commercialisation of novel psychedelic therapies for the treatment of mental health disorders. The Company's lead candidates are based on synthetic psilocybin for the treatment of depression. Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Clinical trials have shown its safety and efficacy in the treatment of depression and other disorders. Woke Pharmaceuticals is developing a novel micro-dose formulation for treatment of moderate depression and a novel high-dose formulation with concomitant psychotherapy for treatment of major depression. Both candidates are expected to enter Phase II trials in 2022 with leading investigators in the field of mental health. For further information, please visit www.wokeph.com.

Purisys LLC Headquartered in Athens, Georgia, USA Purisys is a leading provider of API contract manufacturing and development services including custom synthesis and analytical development services for clinical stage compounds. Purisys' expertise includes extensive scientific and regulatory know-how, state-of-the-art manufacturing technologies and a track record of delivering projects on time. Purisys can develop a broad range of APIs including clinical stage compounds used to treat a variety of indications including therapeutic areas such as cardiovascular, central nervous system, mental health, and oncological drugs. The company has a long-term, successful regulatory track record in the pharmaceutical industry with a commitment to high purity, consistency, and compliance. Purisys also has a comprehensive set of CDMO offerings and a robust reference standard program to support the pharmaceutical industry's delivery of innovative new therapies to patients.